ArticleScientific reports2023
A novel model of the continual reassessment method in Phase I trial.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the model-based designs, the continual reassessment method (CRM) is widely used to identify the maximum tolerated dose (MTD) in phase I clinical trials. To improve the performance of classic CRM models, we propose a new CRM and its dose-toxicity probability function based on the Cox model whatever the treatment response is immediately observed or delayed. In the process of dose-finding trial, we can use our model in situations when either the response is delayed or not and can derive the likelihood function and posterior mean toxicity probabilities to find the MTD. Simulation is carried out to evaluate the performance of the proposed model with the classic CRM models. We also evaluate the operating characteristics of the proposed model by the Efficiency, Accuracy, Reliability, and Safety (EARS) criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.